E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
local advanced metastatic breat cancer, second line therapy for patients who did not respond to treatment with anthracyclines or taxanes or are not suitable for such treatment |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027475 |
E.1.2 | Term | Metastatic breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary study goal is the evaluation of Progression-free survival (PFS) |
|
E.2.2 | Secondary objectives of the trial |
As secondary aim the following parameters will be determined for all participating patients:
1. Safety and Tolerability - All adverse events - Serious adverse events - All side effects of the study medication - Serious side effects - Adverse events that lead to temporary or complete discontinuation of the study treatment - Rates and causes of death 2. Rate of Progression Free Survival after 6 months (6 months PFSR) 3. Overall survival (OS) 4. Response rate (CR, PR)
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
a. Establishment of a tumour tissue repository, Version 2.0, date 24.10.2011
b. Determination of PI3KCA Status, Version 2.0, date 24.10.2011
|
|
E.3 | Principal inclusion criteria |
1. Dated and signed patient informed consent before start of any in the protocol specified procedures 2. Histologically or cytologically confirmed Her2/neu negative, metastatic or locally advanced breast cancer, including inoperable local relapse, with measureable or non-measureable lesions for which - a palliative second line chemotherapy is indicated. Anti-hormone palliative pretreatments do not count as separate treatment lines - treatment with anthracycline and/or taxanes has failed or is not suitable - and which cannot be adequately treated by operation or radiotherapy on its own 3. An exclusive anti-hormone therapy is not sufficient for the patient 4. ECOG Performance Status of 0-2 5. Women, ≥ 18 years of age 6. Life expectancy of at least 12 weeks. 7. Adequate bone marrow, liver and renal function (according to SmPC of Vinorelbine, Afinitor®) based on laboratory assessments raised within 7 days prior to start of study treatment. - Haemoglobin ≥ 9.0 g/dl - Absolute neutrophil count (ANC) ≥ 2,000/mm³ - Thrombocytes ≥ 100,000/µl - INR ≥ 2 - Serum bilirubin ≤ 1.5x upper limit of normal ( in patients with known Gilbert syndrome, total bilirubin ≤ 3 x upper limit of normal, with direct bilirubin ≤ 1.5x upper limit of normal - ALT and AST ≤ 2.5x upper limit of normal (≤ 5x upper limit of normal in subjects with liver metastases) - Serum cholesterol ≤ 300 mg/dl or 7.75 mmol/l and triglycerides ≤ 2.5x upper limit of normal (with lipid lowering drugs permitted) - Serum creatinin ≤ 2x upper limit of normal 8. Documentation of a negative pregnancy test in women of childbearing potential within 7 days prior to start of study. Sexual active pre-menopausal women are required to use adequate contraception throughout the duration of the study, except for oestrogen containing contraceptives. |
|
E.4 | Principal exclusion criteria |
1. Previous treatment with Vinorelbine or an inhibitor of mTOR 2. Treatment with other study medication within 28 days before start of treatment 3. Patients who have received prior radiotherapy to ≥ 25% of the bone marrow 4. Other tumours in the previous 5 years with exception of an adequately treated basal cell carcinoma of the skin or a pre-invasive cervix carcinoma 5. Simultaneous use of known CYP3A4 inducers (e.g. Phenytoin, Rifampicin) or inhibitors of this enzyme (e.g. Itraconazole, Ketoconazole), therefore also use of mistletoe, St John’s wort or grapefruit juice 6. Patients to whom at least one of the conditions applies: - Substance abuse - medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results as judged by the investigator - Legal incapacity or limited legal capacity - Subjects who are unable to take oral medication - Any condition that could jeopardise the safety of the patient and their compliance in the study as judged by the investigator 7. History of cardiac dysfunction including one of the following: - Myocardial infarction by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function - History of documented congestive heart failure (NYHA ≥ 3) - Documented cardiomyopathy 8. Known HIV infection or chronic hepatitis B or C or history of hepatitis B or C 9. Active clinically relevant infection (> grade 2 NCI-CTC Version 4.03) 10. Clinical or radiological detection of CNS metastases 11. Patients receiving concomitant immunosuppressive agents or chronic use of corticosteroids at the time of study entry except in cases outlined below: - topical applications (e.g. rash,) inhaled sprays, (e.g. obstructive airway diseases) eye drops or local injections (e.g. intra-articular) are allowed 12. Active bleeding diathesis or an oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the INR ≤ 2) 13. Kidney function disorder requiring dialysis 14. Seriously impaired liver function (Child-Pugh, class C) 15. Known hypersensitivity reaction to Vinorelbine or Everolimus 16. Pregnant or breast-feeding subjects |
|
E.5 End points |
E.5.1 | Primary end point(s) |
evaluation of progression free survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
As secondary aim the following parameters will be determined for all participating patients:
1. Safety and Tolerability - All adverse events - Serious adverse events - All side effects of the study medication - Serious side effects - Adverse events that lead to temporary or complete discontinuation of the study treatment - Rates and causes of death 2. Rate of Progression Free Survival after 6 months (6 months PFSR) 3. Overall survival (OS) 4. Response rate (CR, PR) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 40 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is defined as last visit of the patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |